TMC649 News - LARVOL Sigma

||||||||||  TMC649 / J&J, Medivir
Trial termination, Combination therapy, Monotherapy:  TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin (clinicaltrials.gov) -  Dec 1, 2011
P1, N=14, Terminated,  Sponsor: Tibotec BVBA
Recruiting --> Terminated; Antiviral activity was considered insufficient to warrant further clinical development of TMC649128.

||||||||||  TMC649 / J&J, Medivir
Enrollment change, Combination therapy, Monotherapy:  TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin (clinicaltrials.gov) -  Dec 1, 2011
P1, N=14, Terminated,  Sponsor: Tibotec BVBA
Recruiting --> Terminated; Antiviral activity was considered insufficient to warrant further clinical development of TMC649128. N=50 --> 14

||||||||||  TMC649 / J&J, Medivir
Trial completion:  TMC649128HPC1001 - First In-human Trial to Examine Safety, Tolerability, and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses of TMC649128 in Healthy Volunteers (clinicaltrials.gov) -  Nov 30, 2011
P1, N=54, Completed,  Sponsor: Tibotec Pharmaceuticals, Ireland
N=50 --> 14 Active, not recruiting --> Completed



	Diseases Companies Products Productz Mechanisms of Action Sites